



Press release

Montpellier, September 18, 2017

Intrasense, Harvard and Zhejiang (China) teaching hospitals finalists for The Galien - MedStartup 2017 Award

Intrasense (FR0011179886 - ALINS), specialist in medical image solutions, is pleased to announce its nomination for the Prix Galien - MedStartup 2017, awarded by The Galien Foundation and Business.

A reward of world-class excellence

The Prix Galien - MedStartup fosters and rewards the most promising companies that develop collaborative projects with innovative partners located in North America.

On October 26, 2017, the Prix Galien - attributed by a [jury](#) made up of world-renowned figures - will reward the Franco-American project that best combines innovation, scientific excellence and market potential for healthcare.

The software publisher brought to light for a highly innovative project

After a selection process started in October 2016, Intrasense is now part of the three finalists in the category "Best collaboration or partnership with academia leading to a breakthrough solution".

The presented project allows the development of imaging biomarkers for liver tumors that will assess at a very early stage and with an unprecedented reliability the efficiency of drug-based therapies in liver cancers.

This project is the result of the collaboration with two very renowned partners:

- Massachusetts General Hospital, Boston, one of the most prestigious American teaching hospital, affiliated to Harvard University
- First Affiliated Hospital of Zhejiang University, a leading teaching hospital in China.

"This project is one of the most ambitious projects in which we have been participating, offering a very high potential market and the opportunity to work with complementary and highly-qualified partners" said Stephane CHEMOUNY, Chairman and Chief Executive Officer of Intrasense.



“The MGH Research team is creating an innovative biomarker that we are implementing in our [Myrian platform](#), while the First Affiliated Hospital is confronting it with the clinical reality of the thousand patients treated annually. We are very proud to be part of the finalists in the competition and we look forward to the announcement of the prize-winners.”

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled ‘innovative company’ by the BPI and invested more than 9 million euros in Research & Development since its creation. For more information, please visit www.intrasense.fr.

About The Galien Foundation

The Galien Foundation rewards excellence in scientific innovation dedicated to healthcare. This non-profit foundation that was created in France 45 years ago supervises and manages the activities associated to the Prix Galien, an international award that promotes the achievements improving the human condition through the development of innovative therapies. For more information, please visit www.galienfoundation.org.

About Business France

Business France is a French organization aiming at supporting and accelerating the development of French companies abroad as well as promoting foreign investments in France. For more information, please visit www.businessfrance.fr.

Contacts

Intrasense
Stéphane Chemouny
Chairman and Chief Executive Officer
Christophe Lamboeuf
Deputy Managing Director
Tel: 01 48 04 32 83
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Valentine Brouchet
Pierre Laurent
Tel: 01 44 71 94 96
intrasense@newcap.eu